Paper Details

  1. Home
  2. Paper Details

Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.

Author: DressmanMarlene A, FisherDennis M, Flynn-EvansErin E, HullJoseph T, LavedanChristian, LicameleLouis, LockleySteven W, PolymeropoulosMihael H, TorresRosarelis, XiaoChangfu

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the safety and efficacy of tasimelteon, a novel dual-melatonin receptor agonist, in patients with non-24-hour sleep-wake disorder.
Paper Details　
Original Abstract of the Article :
Most totally blind people have non-24-hour sleep-wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker. In two consecutive placebo-controlled trials (SET and RESET), we assessed safety and efficacy (in terms of circadian entrainme...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(15)60031-9

データ提供：米国国立医学図書館（NLM）

Tasimelteon: A New Hope for Non-24-Hour Sleep-Wake Disorder

The world of [sleep medicine] is constantly seeking new ways to treat [non-24-hour sleep-wake disorder], a rare and debilitating circadian rhythm disorder. This study investigates the safety and efficacy of [tasimelteon], a [novel dual-melatonin receptor agonist], for the treatment of [non-24-hour sleep-wake disorder] in [totally blind people]. It's like searching for a hidden oasis in the desert of sleep disorders; every new treatment offers hope for those struggling with these conditions.

Tasimelteon's Potential for Treating Non-24-Hour Sleep-Wake Disorder

The researchers found that [tasimelteon] was well-tolerated and showed [promising efficacy] in [entraining and maintaining circadian rhythms] in [totally blind patients]. This is like finding a spring of water that helps quench the thirst of those struggling with sleep disturbances; tasimelteon offers hope for restoring normal sleep patterns.

Navigating the Challenges of Circadian Rhythm Disorders

This research provides a valuable new option for treating [non-24-hour sleep-wake disorder] and offers hope for patients seeking relief from this challenging condition. It's like finding a safe path through the desert of sleep disorders; tasimelteon offers a way to restore balance and improve quality of life.

Dr.Camel's Conclusion

This study is a testament to the ongoing efforts to improve the lives of those struggling with [circadian rhythm disorders]. It's like discovering a new oasis in the desert of sleep research; tasimelteon offers a promising new treatment option for [non-24-hour sleep-wake disorder], bringing hope for a better night's sleep for those who need it most.

Date :
  1. Date Completed 2015-11-20
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26466871

DOI: Digital Object Identifier

10.1016/S0140-6736(15)60031-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.